0750 GMT - Galderma posted strong first-quarter sales figures that increase confidence in its full-year guidance, RBC Capital Markets analysts Alistair Campbell and Charles Weston say in a research note. The Swiss skincare company reiterated its guidance for net sales growth at 10-12% at constant currency. However, it now includes the impact of recently announced U.S. tariffs on its fillers and biostimulators business in the U.S., which accounts for around 9% of total sales, the analysts say. Shares trade 6.2% higher at 85.60 Swiss francs. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。